Developing in Vivo Gene Editors that Target Liver Diseases

While gene editing therapies promise to dramatically change the way that rare genetic diseases are treated, one challenge has been to find ways to deliver them directly into the body rather than first altering a patient’s cells in the lab and reinfusing them. iECURE is developing mutation agnostic in vivo gene editing therapies to address liver diseases. The company has exclusive licensing rights to three liver disorder programs from the University of Pennsylvania’s Gene Therapy Program and an option to license more than 10 additional candidates. We spoke to Joe Truitt, CEO of iECURE, about its in vivo gene editing therapies, its focus on liver diseases, and how it’s leveraging its partnership with Penn’s Gene Therapy Program.